A review of nanoparticle drug delivery systems responsive to endogenous breast cancer microenvironment

Zou, Tengteng; Lü, Wenping; Mezhuev, Ya. O.; Lan, Meng; Li, Lihong; Liu, Fengjie; Cai, Tiange; Wu, Xiaoyu; Cai, Yu

doi:10.1016/j.ejpb.2021.05.029

Cited by 29 publications

(9 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, the nanomedicine microenvironment was evaluated. The stimulus drug delivery system is an intelligent drug delivery system that can cause corresponding physical or chemical changes in the microenvironment to achieve controlled release of drugs ( Zou T. et al, 2021 ). Currently, many smart nanomedicines that respond to external stimuli, such as light, magnetic field, and ultrasound, as well as internal stimuli, such as pH, temperature, enzymes, and redox potential reactions, have been explored ( Zhou et al, 2018 ; Li J. et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Synergistic effect of GF9 and streptomycin on relieving gram-negative bacteria-induced sepsis

Wei

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Triggering receptor expressed on myeloid cells-1 (TREM-1) regulates inflammation and promotes a vigorous immune response. GF9 is one of the peptides that inhibit the mTREM-1 signaling pathway, thus reducing the inflammatory mediators in diseases including sepsis. Nanotechnology could offer a new complementary strategy for diseases. Streptomycin is also one treatment of sepsis. However, the role of nanoparticles delivered GF9 combined with streptomycin on sepsis had never been discovered. In the present study, cecal ligation and puncture (CLP) and lipopolysaccharide [LPS, Escherichia coli (E. coli) O111:B4] sepsis models were constructed. SDS-PAGE was used to evaluate the size of nano drugs; Western blot was used to detect the protein levels of MMP2 and TREM-1 in cells. The levels of TNF-α and IL-6 were detected by ELISA. Histopathological changes were observed by HE staining. And the nanomedicines of GF9-HFn/Str were successfully constructed. The size of GF9-HFn/Str is 36 kD. The ferritin-based nanoparticle plays a vital role in delivering streptomycin into cells and tissues. GF9 (1.6 μM) and streptomycin (40 μM) co-delivery nanomedicine showed a better effect on promoting overall survival, decreasing E. coli, significantly suppressed the expression levels of inflammatory factors (TNF-α and IL-6), and can reduce lung injury. Our study demonstrated that combination delivery of nanomedicine GF9 and streptomycin have a better effect on overall survival rate, anti-inflammatory, and anti-bacterial in sepsis. Our present study revealed a new potential therapeutic method for sepsis.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic effect of GF9 and streptomycin on relieving gram-negative bacteria-induced sepsis

Wei

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Nano-drug delivery systems (NDDS) and nanomedicine have opened a new therapeutic era with specific advantages, including improved stability and biocompatibility, enhanced permeability and retention effect, and precise targeting over conventional drug delivery systems, hence reducing the adverse effects of anticancer drugs [ 314 , 315 ]. Moreover, Nanocarriers (NCs) or Nanoparticles (NPs) raise big hopes to overcome cancer-related drug resistance and are considered to enhance immunotherapy, as well as reverse the tumor immunosuppressive microenvironment [ 316 , 317 , 318 ].…”

Section: Future Perspectives and Novel Strategies For Breast Cancermentioning

confidence: 99%

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Sarvari

Ramírez-Díaz

et al. 2022

IJMS

View full text Add to dashboard Cite

Epigenetic modifications are known to regulate cell phenotype during cancer progression, including breast cancer. Unlike genetic alterations, changes in the epigenome are reversible, thus potentially reversed by epi-drugs. Breast cancer, the most common cause of cancer death worldwide in women, encompasses multiple histopathological and molecular subtypes. Several lines of evidence demonstrated distortion of the epigenetic landscape in breast cancer. Interestingly, mammary cells isolated from breast cancer patients and cultured ex vivo maintained the tumorigenic phenotype and exhibited aberrant epigenetic modifications. Recent studies indicated that the therapeutic efficiency for breast cancer regimens has increased over time, resulting in reduced mortality. Future medical treatment for breast cancer patients, however, will likely depend upon a better understanding of epigenetic modifications. The present review aims to outline different epigenetic mechanisms including DNA methylation, histone modifications, and ncRNAs with their impact on breast cancer, as well as to discuss studies highlighting the central role of epigenetic mechanisms in breast cancer pathogenesis. We propose new research areas that may facilitate locus-specific epigenome editing as breast cancer therapeutics.

show abstract

“…The presence of DHA reduced membrane rigidity and enhanced MMC uptake in an MDR breast cancer cell line. The intracellularly released MMC was then bioactivated inducing a chain lipid peroxidation facilitated by DHA and causing oxidative damage to mitochondria and apoptosis. ,, A complete description of all such examples is beyond the scope of this review. The readers are referred to detailed presentations of the PLN carrier systems in previous publications. ,, …”

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

“…The presence of fibrotic stroma, higher interstitial fluid pressure, and hypovascularity impedes deep tumor penetration of drugs (large molecules) and drug-loaded NPs. , Thus, receptor-mediated active transport strategies are exploited to mitigate such challenges. In this context, the presence of overexpressed enzymes in the TME was utilized as stimuli to design a polymer–drug NPs to achieve enhanced tumor penetration and efficacy. − For instance, γ-glutamyl transpeptidase (an enzyme overexpressed at the endothelial and tumor cells)-responsive camptothecin-polymer conjugate was developed to actively infiltrate through tumor cells via transcytosis . Upon contact with the endothelial cells of tumor vasculature, γ-glutamyl transpeptidase interacted with the NPs and converted the neutral NPs into a cationic one which then underwent caveolae-mediated endocytosis and transcytosis, leading to both transcellular and transendothelial transport of NPs and facilitated deep tumor penetration and antitumor efficacy against orthotopic mice pancreatic cancer.…”

Section: Multitargeted and Intracellularly Activated Nanomedicinementioning

confidence: 99%

“…Most nanocarriers are designed to overcome macroscopic barriers by reducing uptake by the liver and the spleen and to increase tumor accumulation via enhanced permeability and retention (EPR) effects and/or active targeting; however, their penetration into the deep tumor tissue is not guaranteed due to the microscopic barrier. Recent studies suggest that receptor-mediated transcytosis across the endothelial cells may play an important role in promoting tumor uptake and tissue penetration of NPs. − NPs with TME-responsive changes in size, shape, and drug release can also facilitate tumor tissue penetration. − Even though some NPs can reach the cancer cell surface, their cellular uptake and efficient drug release to the site of drug action are often unrealized, which is largely attributable to cell membrane rigidity in MDR cells, lysosomal entrapment, and undesirable drug release profiles. ,,, As a result, the efficacy of NP-based cancer therapeutics frequently suffer from poor target penetration (<5% of administered dose), and exhibit subtherapeutic drug levels within cancer cells. ,, …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Ahmed

Liu

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. Firsthand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine-and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.

show abstract

A review of nanoparticle drug delivery systems responsive to endogenous breast cancer microenvironment

Cited by 29 publications

References 159 publications

Synergistic effect of GF9 and streptomycin on relieving gram-negative bacteria-induced sepsis

Synergistic effect of GF9 and streptomycin on relieving gram-negative bacteria-induced sepsis

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Contact Info

Product

Resources

About